Health Condition 1: D490- Neoplasm of unspecified behavior of digestive system
Conditions
Interventions
Control Intervention1: Nil: Nil
Sponsors
Dr Ashwin Oommen Philips
Eligibility
Inclusion criteria
Inclusion criteria: Age:All adult cancer patients aged 18 years and above. MMR Testing: Patients who have undergone MMR testing using Immunohistochemistry (IHC) for MLH1, PMS2, MSH2, and MSH6 proteins. Cancer Type: Patients diagnosed with any type of solid malignancy, including colorectal, endometrial, ovarian, and other cancers where MMR testing is clinically indicated. Treatment History: Patients who have completed their primary cancer treatment (surgery, chemotherapy, radiation) and for whom MMR testing was part of the diagnostic or therapeutic decision-making process. Clinical Data Availability: Patients with complete clinical records, including demographic data, tumor characteristics, treatment details, and MMR test results. Follow-up Data: Patients with documented follow-up data to assess treatment outcomes, response to therapy, and survival.
Exclusion criteria
Exclusion criteria: Pediatric Patients: Patients younger than 18 years of age. Incomplete Records: Patients with incomplete clinical records, particularly those missing MMR test results or key demographic and tumor-related information. Non-Solid Tumors: Patients with hematological malignancies or other non-solid tumors that do not typically undergo MMR testing. No Follow-up Data: Patients with no available follow-up data, making it impossible to assess treatment outcomes and survival.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine the prevalence of MSI testing and its outcomes in solid tumours in a tertiary care centreTimepoint: 0,6,9 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Analyze the demographic details of cancer patients on whom Mismatch Repair Gene Testing (MMR) was done at a tertiary cancer center in India. Timepoint: 23rdAugust 2024 to 23rd January 2025;Assess the frequency and distribution of MMR deficiency among cancer patients in the study population. Timepoint: 23rd August 2024 to 23rd January 2025;Identify any correlations between MMR status and clinicopathological features, such as age, gender, tumor location, and histological subtype. Timepoint: 23rd August 2024 to 23rd January 2025 | — |
Countries
India
Contacts
Public ContactDr Ashwin Oommen Philips
Amala Institute of Medical Sciences
Outcome results
None listed